Abstract-Diabetes mellitus-induced oxidative stress causes increased renal oxygen consumption and intrarenal tissue hypoxia. Nitric oxide is an important determinant of renal oxygen consumption and electrolyte transport efficiency. The present study investigates whether l-arginine or l-citrulline to promote nitric oxide production prevents the diabetes mellitus-induced kidney dysfunction. Glomerular filtration rate, renal blood flow, in vivo oxygen consumption, tissue oxygen tension, and proteinuria were investigated in control and streptozotocin-diabetic rats with and without chronic l-arginine or l-citrulline treatment for 3 weeks. Untreated and l-arginine-treated diabetic rats displayed increased glomerular filtration rate (2600±162 versus 1599±127 and 2290±171 versus 1739±138 µL/min per kidney), whereas l-citrulline prevented the increase (1227±126 versus 1375±88 µL/min per kidney). Filtration fraction was increased in untreated diabetic rats because of the increase in glomerular filtration rate but not in l-arginine-or l-citrullinetreated diabetic rats. Urinary protein excretion was increased in untreated and l-arginine-treated diabetic rats (142±25 versus 75±7 and 128±7 versus 89±7 µg/min per kidney) but not in diabetic rats administered l-citrulline (67±7 versus 61±5 µg/min per kidney). The diabetes mellitus-induced tissue hypoxia, because of elevated oxygen consumption, was unaltered by any of the treatments. l-citrulline administered to diabetic rats increases plasma l-arginine concentration, which prevents the diabetes mellitus-induced glomerular hyperfiltration, filtration fraction, and proteinuria, possibly by a vascular effect. (Hypertension. 2014;64:00-00.) • Online Data Supplement
S
ustained hyperglycemia affects kidney function, and insulinopenic diabetes mellitus is a major cause of end-stage renal disease requiring renal replacement therapy. 1 Renal alterations including elevated glomerular filtration rate (GFR) and intrarenal hypoxia 2, 3 can be observed early after the onset of diabetes mellitus. Nitric oxide (NO) is an important factor, regulating both vascular tone and, therefore, blood flow, 4 as well as tubular electrolyte transport via a direct interference with tubular transporters 5 and inhibition of mitochondria respiration. 6 Reduced NO production or increased degradation may contribute to kidney dysfunction in different pathological conditions, such as diabetes mellitus and hypertension. NO is synthesized by 3 different NO-synthase isoforms: endothelial NO synthase (eNOS), inducible NO synthase, and neuronal NO synthase. All NOS isoforms convert l-arginine (l-Arg) to l-citrulline (l-Cit) and NO with the cofactors tetrahydrobiopterin, nicotinamide adenine dinucleotide phosphate, and molecular oxygen. NO production is regulated by substrate availability 7 and cofactor availability, mainly tetrahydrobiopterin, 8 and also by the levels of endogenous inhibitors such as asymmetrical dimethylarginine. 9 It has been debated whether the availability of the substrate l-Arg is of importance. The intracellular concentration of l-Arg is usually >100 µmol/L, 10 and the Michaelis-Menten constant (K m ) of NOS for l-Arg is <5 µmol/L. 11 However, it has been demonstrated that l-Arg supplementation stimulates NO production, a phenomenon referred to as the arginine paradox, 12 resulting in endotheliumdependent vasodilation. The main source of l-Arg for NO synthesis is extracellular because of the caveolar complex between eNOS and cationic amino acid transporter 1 (CAT1) in endothelial cells, shielding NOS from the high intracellular l-Arg concentration, suggesting that CAT1 presents l-Arg to eNOS. [13] [14] [15] l-Arg uptake in renal epithelial cells is mediated by system y by either system y + or y + L. System y + mediates cellular uptake of cationic amino acids, and system y + L mediates uptake of both cationic and neutral amino acids. Uptake of cationic amino acids is sodium independent, whereas neutral amino acid uptake by y + L is sodium dependent. 16 System y + is mainly represented by CAT1 in the kidney. 7 The cellular uptake is determined by the relative concentration of each amino acid in relation to other amino acids sharing the same transporter. Therefore, reduced levels of l-Arg or increased levels of competing amino acids has the potential to affect l-Arg transport. Increasing extracellular l-Arg concentration promotes NO production, whereas addition of l-lysine (l-Lys) or l-ornithine (lOrn) reduces l-Arg transport and subsequently decreases renal NO production. 7 Furthermore, diabetic rats have both lower renomedullary NO bioavailability and reduced plasma levels of l-Arg, 17 and it has been demonstrated that acute administration of l-Arg in combination with the antioxidant α-tocopherol improves NO bioavailability in both control and diabetic rats. 18 Around 10% of plasma l-Arg originates from de novo synthesis from l-Cit.
19 l-Cit is scarce in food but is produced from glutamine in enterocytes 20 and then converted to l-Arg in the proximal tubules of the kidneys. 21 We hypothesize that chronic l-Arg or l-Cit supplementations improve kidney NO synthesis, resulting in protected kidney function in diabetic rats.
Materials and Methods
The experimental protocols are detailed in the online-only Data Supplement. All procedures were approved by the local animal ethics committee at Uppsala University and in accordance with National Institute of Health guidelines for the Care and Use of Laboratory Animals. Briefly, control and streptozotocin-diabetic SpragueDawley rats were supplemented with vehicle, l-Arg, or l-Cit in the drinking water throughout the 3 weeks of diabetes mellitus. Kidney function was evaluated under thiobutabarbital anesthesia (Inactin, Sigma Aldrich; single dose of 120 mg/kg IP) during baseline period and after nonselective NOS inhibition by Nω-Nitro-l-arginine methyl ester hydrochloride (L-NAME).
Statistical Analysis
All statistical analyses were performed using GraphPad Prism software (GraphPad Software Inc, San Diego, CA). All in vivo data were analyzed by repeated measure 2-way ANOVA followed by Bonferroni multiple comparison test. Data presented in Table 2 were analyzed by 1-way ANOVA followed by Fisher Least Significant Difference (LSD) test. Data presented in Table S1 in the online-only Data Supplement were analyzed by 2-way ANOVA followed by Fisher LSD test. Descriptive statistics are expressed as means±SEM. For all analyses, P<0.05 was considered significant.
Result
All diabetic animals were hyperglycemic compared with controls, and all diabetic groups developed similar degree of hyperglycemia (Table S2) . Hematocrit was similar in all groups, but body weight was lower in diabetic rats (Table S2) . Baseline mean arterial pressure was lower in the diabetic rats compared with controls, and in all groups, mean arterial pressure increased after administration of L-NAME (Table 1) . Baseline GFR was higher in untreated diabetic rats and diabetic rats+l-Arg compared with corresponding controls ( Figure 1A and 1B), whereas GFR in diabetic rats+l-Cit was not significantly different from corresponding controls ( Figure 1C) . Renal blood flow was higher in untreated diabetic rats compared with controls but similar to controls in diabetic rats+l-Arg and diabetic rats+l-Cit. All groups displayed reduced renal blood flow after L-NAME (Table 1) . Accordingly, filtration fraction (FF) was elevated in untreated diabetic rats, but diabetic rats+l-Arg and diabetic rats+l-Cit presented with similar FF as corresponding controls. L-NAME increased FF in all groups (Table 1) . Oxygen consumption (QO 2 ) was higher in all diabetic groups compared with corresponding controls, and L-NAME increased QO 2 in untreated controls and all diabetic groups (Table 1) .
Untreated diabetic rats and diabetic rats+l-Arg had elevated urinary protein excretion compared with corresponding controls, which was prevented by l-Cit (Figure 2A-2C) . The full amino acid profiles for the different groups are presented in Table S1 . In brief, plasma l-Arg was reduced in untreated diabetic rats and prevented by l-Arg treatment ( Figure 3A) . However, l-Cit increased plasma l-Arg levels in both controls and diabetic rats. CAT1 transport of l-Arg is competitively inhibited by l-Orn and l-Lys. Plasma l-Orn was increased in both groups treated with l-Arg and controls+l-Cit but similar to untreated group in diabetic rats+l-Cit. l-Lys was significantly decreased in all diabetic groups compared with controls (Table S1 ). Taking this into consideration, the ratio (l-Arg/lLys+l-Orn) was calculated. Plasma ratios of l-Arg/l-Lys+l-Orn were similar in untreated groups and not affected by l-Arg treatment ( Figure 3B ). However, l-Cit significantly improved this parameter in both controls and diabetic rats. Urinary excretion of thiobarbituric reactive substances (TBARS) was increased in all diabetic groups (Table 2) . L-NAME significantly decreased TBARS excretion in diabetic rats+l-Arg but had no effect in untreated or l-Cit-treated groups. Plasma TBARS was increased in all diabetic groups and further increased in diabetic rats+l-Arg. Urinary NOx excretion was increased in untreated diabetic rats and diabetic rats+l-Arg but not statistically increased in diabetic rats+l-Cit compared with corresponding controls. In contrast, urinary excretion of cGMP was not affected by diabetes mellitus or any of the chronic treatments. Arginase activity was significantly increased in all diabetic groups and unaffected by the treatments (Table 2) .
Discussion
The main new finding of this study is that l-Cit supplementation throughout the course of diabetes mellitus increases plasma l-Arg concentration and prevents the diabetes mellitus-induced increase in GFR and proteinuria, whereas similar l-Arg supplementation fails to do so.
Reduced NO bioavailability in diabetes mellitus could be initiated by decreased plasma l-Arg concentration because extracellular l-Arg concentration and its transport over the plasma membrane via CAT are a rate-limiting step for NO production. In the isolated perfused kidney, addition of competing cationic amino acids results in competitive inhibition of l-Arg transport, with subsequent reduction in NO production results in a dose-dependent increase in renal vascular resistance. 22 Plasma l-Arg concentration is reduced in diabetes mellitus, partly because of increased hepatic uptake via CAT2A with a subsequent arginase-mediated degradation. 18 However, l-Arg supplementation failed to reduce in vivo QO 2 , GFR, and proteinuria in the present study. This is in contrast to the work by Reyes and coworkers in which l-Arg supplementation for 14 weeks normalized GFR and proteinuria. 23 However, they failed to increase plasma l-Arg, which is in contrast to the present study in which l-Arg treatment prevented diabetes mellitusmediated decrease in plasma l-Arg. However, l-Cit treatment increased plasma l-Arg concentration in diabetes mellitus. Possible explanations include that elevated l-Arg levels result in a feed-forward mechanism upregulating hepatic l-Arg uptake and arginase activity, which together with the diabetes mellitus-induced increase in arginase I expression and activity contribute to l-Arg being less efficient in increasing plasma l-Arg. 18, 24 Increased degradation of l-Arg during l-Arg supplementation is indicated by increased plasma l-Orn in both l-Arg-treated groups in the present study, which is in contrast to the normal levels observed in diabetic rats supplemented with l-Cit. Furthermore, l-Arg stimulates insulin release, which is a prerequisite for l-Arg transport by CAT1, and may constitute a problem in insulinopenic diabetes mellitus. 25, 26 A novel approach to avoid increased hepatic l-Arg degradation is to use l-Cit supplementation. l-Cit is endogenously synthesized from l-glutamine in the intestines and released to the venous blood, 20 filtered in the glomeruli, and subsequently taken up by the proximal tubule. Proximal tubular cells express both argininosuccinate synthase and argininosuccinate lyase 27, 28 and can, therefore, convert l-Cit to lArg. 21 The intestinal-renal axis of de novo synthesis of l-Arg from l-glutamine has been demonstrated using radiolabeled l-glutamine. 29 Argininosuccinate lyase was recently reported to be crucial for NO production by functioning as an adaptor protein connecting CAT1 and NOS to form a functional complex. 30 This suggests that de novo synthesis of l-Arg is occurring in close proximity to NOS. In addition, l-Cit can reduce both hepatic and vascular arginase activity in diabetes mellitus, which may reduce l-Arg degradation and thereby further contribute to increased plasma l-Arg after l-Cit supplementation. 31 This is further supported by the normal l-Orn levels in l-Cit supplemented diabetic rats. K m for l-Arg transport via CAT1 is estimated to 100 to 250 µmol/L, with similar values reported for l-Lys and l-Orn. 32, 33 Individual concentrations of l-Arg, l-Lys, and l-Orn will, therefore, determine CAT1 transport of each amino acid, and the ratio between l-Arg compared with l-Lys and l-Orn influences cellular transport of l-Arg. Decreased renal medullary NO production after infusion of l-Orn or l-Lys in control rats has been reported. 7 The ratios between l-Arg to l-Lys and l-Orn (l-Arg/l-Lys+l-Orn) were 0.14:1 and 0.13:1 in untreated control and diabetes mellitus, respectively. This was not improved in diabetic rats supplemented with l-Arg but markedly improved to 0.64:1 and 0.51:1 in controls and diabetic rats supplemented with lCit. This improvement is the result of significantly increased plasma l-Arg after l-Cit supplementation and the significantly decreased plasma l-lysine during diabetes mellitus. l-Cit supplementation also affected the levels of other amino acids, but these effects are not thought to affect the NO system and, thus, are beyond the scope of this study.
l-Cit-induced increase in plasma l-Arg concentration in diabetic rats prevented glomerular hyperfiltration without affecting renal blood flow, which resulted in normal FF in these animals. Normalized FF in l-Cit-treated diabetic rats was associated with reduced urinary protein excretion similar to the levels observed in corresponding controls. These data support the notion that lCit treatment results in dilation of the efferent arteriole exceeding that of the afferent arteriole by inducing increased local NO bioavailability, reducing net filtration pressure and, therefore, GFR and also proteinuria. However, these statements should be further solidified using direct micropuncture techniques. Genotypes associated with reduced eNOS expression display increased GFR and urinary albumin excretion independent of mean arterial pressure during diabetes mellitus development. 34 All diabetic groups displayed increased oxidative stress as indicated by increased urinary TBARS excretion, which previously has been shown to correlate well with direct in vivo measurements using electron spin resonance. 35 Interestingly, NOS inhibition in l-Arg-supplemented diabetic rat significantly decreased urinary TBARS excretion, suggesting that uncoupled NOS produces O 2 − in these animals. Also, TBARS concentration in plasma was significantly increased in diabetes mellitus+l-Arg compared with untreated diabetes mellitus, suggesting that l-Arg supplementation increased oxidative stress. Intriguingly, TBARS in renal cortical tissue was not affected by any of the treatments. However, this is in line with the lack of effect on QO 2 and oxygen tension by these treatments. NOS inhibition did not result in any significant reduction in TBARS excretion in untreated diabetic rats or diabetic rats supplemented with l-Cit. However, baseline TBARS excretion was significantly lower in diabetic rats supplemented with l-Cit compared with l-Arg. This could reflect either NO-mediated scavenging of O 2 − or that the increased plasma l-Arg in diabetic rats supplemented with l-Cit prevented NOS uncoupling. It has been shown that decreased lArg concentration promotes O 2 − production from NOS. 36 This indicates that l-Cit is more effective to improve NO synthesis than l-Arg in diseases associated with increased reactive oxygen species and decreased NO bioavailability. These findings are in line with the ineffectiveness and even detrimental effect of l-Arg to improve vascular dysfunction in patients. , and chronically l-citrulline-treated (C) controls and diabetic rats during baseline and after acute nitric oxide synthase inhibition with Nω-Nitro-l-arginine methyl ester hydrochloride (L-NAME). Result from 2-way ANOVA: (A) diabetes mellitus; P<0.05 L-NAME; ns interaction, ns; (B) diabetes mellitus; P<0.05 L-NAME; ns interaction, ns; (C) diabetes mellitus; ns L-NAME; ns interaction, ns. However, in the current setting with long-term l-Cit supplementation, the support for increased NO production is less convincing. Urinary excretion of NOx was increased in both untreated and l-Arg-treated diabetic rats but not in l-Cittreated diabetic rats. However, urinary excretion of cGMP, as an indicator of NO signaling, was not reduced, supporting a concept of maintained NO signaling, despite decreased NO production during l-Cit supplementation.
PROTEINURIA L-CITRULLINE
Arginase activity was increased in diabetic rats and has previously shown to contribute to the development of diabetic nephropathy via an eNOS-dependent mechanism. 38 However, in vitro arginase activity was not affected by either l-Arg or l-Cit in the present study, although l-Cit can allosterically inhibit arginase activity, 39 Plasma l-Orn was not increased, and in combination with significantly increased l-Arg concentration in l-Cit-treated diabetic rats indicate that this anyway occurred in vivo.
Intrarenal hypoxia occurs early after the onset of diabetes mellitus and has emerged as an important factor in the development of diabetic kidney disease [40] [41] [42] and has at least partly been ascribed to reduced NO bioavailability 17 because NO also influences mitochondrial oxygen usage. 6 It has previously been demonstrated that nonselective NOS inhibition increase total kidney QO 2 , despite reduced GFR. 43, 44 This is also supported by the reduced tubular transport efficiency (transported sodium/QO 2 ) after L-NAME in the present study. In contrast, l-Cit supplementation also seems to decrease transported sodium/QO 2 , though mainly via the significantly decreased GFR with direct effects on transported sodium. Basal QO 2 is highly influenced by changes in transported sodium, which would explain the effect of l-Cit supplementation. 45 However, improved kidney function after increased plasma l-Arg levels by l-Cit supplementation was not associated with normalized kidney QO 2 , indicating that the potential NO-mediated beneficial effects not primarily occurred in the energy-demanding tubular structures but in the vasculature.
In conclusion, l-Arg prevents decreased plasma l-Arg concentration in diabetes mellitus but does not improve kidney function. On the contrary, l-Cit supplementation increases plasma l-Arg and prevents the development of diabetes mellitus-induced glomerular hyperfiltration and proteinuria with maintained renal blood flow. The effects seem to be mediated by improved vascular NO signaling.
Perspectives
l-Arg has been used to improve NO production in diseases associated with endothelial dysfunction. However, the results to date do not demonstrate a consistent beneficial effect. In the present study, we demonstrate that l-Cit, to promote endogenous l-Arg production, is a more effective way to improve plasma concentration of l-Arg. Importantly, improved l-Arg levels by l-Cit protected diabetic kidney function by preventing the commonly occurring glomerular hyperfiltration and proteinuria commonly associated with early diabetic nephropathy. These findings provide the basis for a translational study to solidify the role of deranged l-Arg-NO system for the development of nephropathy in type 1 patients with diabetes mellitus. 
Animals and induction of diabetes.
Age-matched Sprague-Dawley rats weighing 250-300 g were purchased from Charles River (Sulzfeld, Germany). They had free access to tap water and standard rat chow. All experiments were performed in accordance with NIH guidelines for use and care of laboratory animals and approved by the Animal Care and Use Committee for Uppsala University. Diabetes was induced by a single injection of streptozotocin (STZ, 55 mg/kg) in the tail vein. Animals were considered diabetic if blood glucose was increased to above 18 mmol/L within 24 hours and remained elevated. Blood glucose concentration was determined with test reagent strips (MediSense, Bedford, MA, USA) in blood samples from the cut tip of the tail.
Experimental groups. The experimental groups consisted of untreated control (n=12), control+L-Arg (n=10), control+L-Cit (n=11), untreated diabetic (n=9), diabetic+L-Arg (n=10) and diabetic+L-Cit (n=10). L-Arg (1.25% to controls and 0.35% to diabetics) or L-Cit (1.20% to controls and 0.20% to diabetics) was administered in the drinking water throughout the course of the study. These doses correspond to a daily dose of 1.0-2.0 g/kg. Diabetes duration was 21 ±5 days and treatments started on the same day as diabetes induction.
Surgical procedures. Acute experiments were performed under thiobutabarbital anesthesia (Inactin, 120 mg/kg for controls and 80 mg/kg for diabetics, ip). Rats were placed on a table with a servo-controlled heating pad maintaining body temperature at 37.5˚C. Animals were tracheotomized and catheters placed in carotid artery for measurement of arterial blood pressure, a femoral artery for blood sampling and a femoral vein for infusion of Ringer solution (5 ml/kg/h for controls and 10 ml/kg/h for diabetics). The bladder was catheterized for drainage. The left kidney was exposed by a subcostal flank incision and immobilized in a plastic cup. Left ureter and renal vein were catheterized for collection of urine and blood samples, respectively. Animals were allowed a 45-minute recovery period after surgery followed by a 30-minute baseline period. Thereafter the non-selective NOS inhibitor N G -nitro-l-arginine methyl ester (L-NAME) was administered intravenously as a bolus dose (10 mg/kg) followed by a continuous infusion (10 mg/kg/h). All parameters were then measured for an additional 30-minute period. 2 ,and PO 2 . GFR was estimated from clearance of 3 H-inulin, which was given as a bolus dose (185 kBq, American Radiolabeled Company, St. Louis, MO, USA) followed by continuous infusion (185 kBq/kg/h) in Ringer solution.
Measurement of GFR, RBF, QO
3 Hinulin activity was determined using standard liquid scintillation technique and GFR calculated according to standard formula. Total RBF was measured using an ultrasound probe (Transonic Systems, Ithaca, NY, USA) placed around the left renal artery. Total kidney oxygen consumption (QO 2 ) was determined from the arterio-venous difference in oxygen content (O 2 ct) multiplied by the RBF according to the formula: O 2 ct=([hemoblobin]*oxygen saturation*1.34+oxygen tension*0.003). PO 2 was measured in renal cortex using modified Clark-type microelectrodes (~10 µm o.d. Unisense, Aarhus, Denmark). Electrodes were twopoint calibrated in water saturated with either Na 2 S 2 O 5 (zero) or air (147 mmHg).
Measurement of urinary protein excretion, TBARS, nitrate/nitrite and arginase activity. Urine flows were determined gravimetrically and urinary protein concentration using DC Protein Assay (Bio-Rad Laboratories, Hercules, CA, USA). Thiobarbituric acids reactive substances (TBARS) were measured fluorometrically after incubating the urine samples with thiobarbituric acid as previously described 1 . Briefly, 100 µl of diluted urine sample was heated to 97˚C for 60 minutes after mixing with 125 µl thiobarbituric acid (Merk, Darmstadt, Germany). Standards were prepared from malondialdehyde-bis-(diethylacetate) (MerkSchuchart, Schuchart, Germany). Samples were cooled on ice and 150 µl of a mixture of methanol and 1 mol/L NaOH (91:9) were added followed by centrifugation, 3000 rpm for five minutes. Fluorescence was measured in the supernatant (ex. 532 nm, em. 553 nm). Nitrate/nitrite (NOx) was measured using a commercially available kit according to instructions from manufacturer (Nitrate/Nitrite Colorimetric Assay Kit, Cayman Chemicals, Ann Arbor, MI, USA. Arginase acitivity was measured by quantifying urea formation in kidney cortex homogenates as previously described. 2 Amino acid analysis. Plasma concentrations of asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and homoarginine were measured with highperformance liquid chromatography (HPLC) with fluorescence detection as described previously, 3 using modified chromatographic separation conditions. 4 For all analytes, the intra-and interassay coefficients of variation were <2% and <4%, respectively. Plasma concentrations of other amino acids, including arginine, were measured with reversed-phase HPLC, using automated precolumn derivatization with ortho-phthaldialdehyde reagent and fluorescence detection, as previously described. 5 For all amino acids, the intra-and interassay coefficients of variation were <4% and <7%, respectively.
Results
Amino acids and related compounds for the different groups are presented in table S1 and various baseline characteristics as well as TBARS and NOx in renal cortical tissue are presented in table S2. 
